Real-world study of atezolizumab for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer.
- You are 18 years or older.
- You have been prescribed atezolizumab as your first treatment.
- You have received up to 3 cycles of atezolizumab so far.
- You are not pregnant or breastfeeding.
- You have no known allergies to atezolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
This study tests a first-line immunotherapy combination (like atezolizumab + bevacizumab or similar drugs) for advanced liver cancer that can't be removed. It aims to see how well these treatments work and how safe they are in real-world patients.
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
This trial tests a drug called atezolizumab, an immunotherapy that helps your immune system fight cancer, in people with advanced non-small cell lung cancer that has high PD-L1 protein (≥50%) and no treatable gene mutations. Researchers will also check a blood marker (c-FLIP) linked to certain immune cells to understand how well the treatment works.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.